

Continuing Education

Schizophrenia and Long-Acting Injectibles

Authors:

Christie Hamm
Pharm.D., 2016
Harrison School of Pharmacy, Auburn University

Jillian Jacobs
Pharm.D., 2016
Harrison School of Pharmacy, Auburn University

Ha Vy Ngo
Pharm.D., 2016
Harrison School of Pharmacy, Auburn University

Corresponding Author:

Wesley Lindsey, Pharm.D.
Associate Clinical Professor of Pharmacy Practice
Drug Information and Learning Resource Center
Harrison School of Pharmacy, Auburn University

Universal Activity #: 0178-0000-16-104-H01-P | 1.25 contact hours (.125 CEUs)

Initial Release Date: July 20, 2016 | Expires: April 20, 2019

QUIZ – SCHIZOPHRENIA AND LONG-ACTING INJECTIBLES | ACPE#: 0178-0000-16-104-H01-P

- Which of the following is a difference between DSM-IV and DSM-V?
 - Characteristics of positive symptoms
 - Characteristics of negative symptoms
 - Change in the number of symptoms needed for diagnosis
 - All of the above
 - What is the predominant neurotransmitter for antipsychotic medications?
 - Serotonin
 - Dopamine
 - Norepinephrine
 - Both A & B
 - Which of the following is classified as a “positive symptom” of schizophrenia?
 - Hallucinations
 - Effective flattening
 - Alogia
 - Impaired attention
 - Which of the following maternal stressors would be a risk for the child developing schizophrenia?
 - STIs
 - Malnutrition
 - Migraine
 - Hypertension
 - Which of the following are contributing factors that play a role in nonadherence?
 - Cost
 - Unreliable transportation
 - Lack of family involvement
 - All of the above
 - What is an important element that will influence treatment success?
 - A therapeutic alliance between psychiatrist and patient
 - A healthy diet
 - Minimal follow-up visits
 - Less social support
 - What are the phases of schizophrenia treatment?
 - First, Second, Third
 - Acute, Stabilization, Stable
 - Acute, Stable, Chronic
 - Severe, Moderate, Controlled
 - What drug class is considered first-line in schizophrenia treatment?
 - SSRI
 - TCA
 - Atypical antipsychotics
 - Typical antipsychotics
 - Which of the following adverse events is associated with atypical antipsychotics?
 - EPS
 - Tardive dyskinesia
 - Sedation
 - All of the above
 - Which of the following is true regarding Aristada and Abilify Maintena?
 - Aristada requires oral titration/overlap
 - Abilify Maintena requires administration every 4 to 6 weeks
 - Abilify Maintena requires oral titration/overlap
 - Abilify Maintena is the prodrug form of aripiprazole
 - Which of the following long-acting injectable antipsychotics has the longest half-life?
 - Invega Trinza
 - Abilify Maintena
 - Aristada
 - Zyprexa Relprevv
 - Which of the following long-acting injectable antipsychotics does not require oral medication titration/overlap?
 - Abilify Maintena
 - Risperdal Consta
 - Haldol Decanoate
 - Zyprexa Relprevv
-

13. Long-acting injectable antipsychotics have been shown to improve which of the following?
- a. Rehospitalization rates
 - b. Progression of schizophrenia
 - c. Leg pain
 - d. All of the above
14. What is the main characteristic of assertive community treatment (ACT)?
- a. It is a hospice program
 - b. It is a 24-hour basis program that provides comprehensive care for schizophrenic patients
 - c. Enrollment fee is based on patient's income
 - d. Once monthly follow-up visit for patient on clozapine
15. How long does it take to see an initial response with antipsychotic medications?
- a. Immediately
 - b. 1-2 weeks
 - c. 2-4 weeks
 - d. 6 months
-

Participant Information:

AL License # _____

Name _____

Address _____

City _____ State _____ Zip _____

E-mail _____

NABP e-Profile # _____

MM/DD (month/day of birth) _____

How long did it take you to read the article and complete this test?

_____ hours _____ minutes

My signature certifies that I have independently taken this CE examination.

CE Assessment Answers				
Please circle your answers (one answer per question)				
1.	A	B	C	D
2.	A	B	C	D
3.	A	B	C	D
4.	A	B	C	D
5.	A	B	C	D
6.	A	B	C	D
7.	A	B	C	D
8.	A	B	C	D
9.	A	B	C	D
10.	A	B	C	D
11.	A	B	C	D
12.	A	B	C	D
13.	A	B	C	D
14.	A	B	C	D
15.	A	B	C	D

Program Evaluation – Must be completed for credit.

Please rate the following items on a scale from 1 (poor) to 4 (excellent).

- | | | | | |
|-----------------------------------|---|---|---|---|
| 1. Overall quality of the article | 1 | 2 | 3 | 4 |
| 2. Relevance to pharmacy practice | 1 | 2 | 3 | 4 |
| 3. Value of the content | 1 | 2 | 3 | 4 |

Please answer each question, marking whether you agree or disagree.

4. This course met the learning objectives. Agree Disagree
5. The article did not promote a particular product or company. Yes No

Impact of the Activity

The information presented (check all that apply):

6. Reinforced my current practice/treatment habits Will improve my practice/patient outcomes
 Provided new ideas or information I expect to use Adds to my knowledge
7. Will the information presented cause you to make any changes in how you do your job? Yes No
8. How committed are you to making these changes?
 (Not committed) 1 2 3 4 (Very committed).
9. Do you feel future activities on this subject matter are necessary and/or important? Yes No

Follow-Up

As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey?

Yes No



The Alabama Pharmacy Association Research and Education Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.